1. CCL19 levels are elevated in Lyme disease cases with PTLDS
CCL19 levels are elevated in Lyme disease cases with PTLDS. Displayed are the median and interquartile range serum levels of CCL19 among 76 Lyme disease patients over time.
CCL19 levels are elevated in Lyme disease cases with PTLDS. Displayed are the median and interquartile range serum levels of CCL19 among 76 Lyme disease patients over time. Lyme disease-exposed participants are divided into the PTLDS, symptoms-only, and return-to-health clinical outcome groups on the basis of self-reported symptoms and survey measurements at 6 months and 1 year posttreatment (25). The median control value (79.28 pg/ml; interquartile range, to pg/ml) is represented by a triangle in the graph. *, P ≤ 0.05 for comparison of each group to the controls; **, P ≤ 0.01 for comparison of each group to the controls.
John N. Aucott et al. Clin. Vaccine Immunol. 2016; doi: /CVI